Researchers reported two complementary advances in adenine base editing. First, a mutation‑reversion study produced minimally evolved ABEs with narrowed editing windows, improved on‑target efficiency and reduced off‑target edits—changes that make these editors more attractive for clinical applications by simplifying enzyme composition while preserving activity. Second, an independent Nature Biotechnology report described in vivo base editing that reversed a neurodevelopmental disorder in preclinical models, presenting a translational proof of concept for therapeutic base editing. Together the studies illustrate both tool refinement and therapeutic validation across the base‑editing field and highlight routes to increase precision while pushing toward in vivo clinical use.